Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Celecoxib in Preventing Skin Cancer

This study has been withdrawn prior to enrollment.
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: October 11, 2001
Last updated: March 21, 2013
Last verified: December 2006

RATIONALE: Celecoxib may be effective in preventing skin cancer by decreasing redness caused by exposure to ultraviolet light and changing potential skin cancer biomarkers. It is not yet known whether celecoxib is more effective than a placebo in preventing skin cancer.

PURPOSE: Randomized phase II trial to study the effectiveness of celecoxib in preventing skin cancer in participants exposed to ultraviolet light.

Condition Intervention Phase
Non-melanomatous Skin Cancer
Drug: celecoxib
Procedure: anti-cytokine therapy
Procedure: antiangiogenesis therapy
Procedure: biological therapy
Procedure: cancer prevention intervention
Procedure: chemoprevention of cancer
Procedure: growth factor antagonist therapy
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Masking: Double-Blind
Primary Purpose: Prevention
Official Title: A Phase II, Double-Blind, Placebo-Controlled Clinical Trial To Assess Celecoxib As A Chemopreventive Agent Inhibiting UV-Induced Erythema And Cutaneous Carcinogenesis As Assessed Through Surrogate Biological Markers In Biopsied Skin After Exposure Of Skin In Normal Volunteers Ages 20-60 Years Old With Fitzpatrick Type I, II, III And IV Skin To UV-Radiation From Artificial Light Sources

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Enrollment: 0
Detailed Description:


  • Determine whether celecoxib decreases ultraviolet(UV)-induced erythema and affects surrogate biomarkers of potential neoplastic change in participants with Fitzpatrick type I-IV skin exposed to UV light.

OUTLINE: This is a randomized, double-blind, placebo-controlled study. Participants are randomized to one of two treatment arms.

  • Arm I: Participants receive oral celecoxib twice daily for approximately 120 days.
  • Arm II: Participants receive oral placebo twice daily for approximately 120 days.

Skin biopsies of UV-exposed sites are evaluated.

Participants are followed for up to 5 weeks post-treatment.

PROJECTED ACCRUAL: A total of 36 participants (18 per arm) will be accrued for this study within 8 months.


Ages Eligible for Study:   20 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Fitzpatrick type I-IV skin
  • No history of photosensitivity (e.g., systemic or discoid lupus erythematosus, polymorphous light eruption, or photocontact dermatitis)
  • No history of abnormal tanning responses or other unusual reactions to natural or artificial light sources
  • Willing to wear sun-protective clothing and SPF 15-49 sunscreen
  • Willing and able to restrict the frequency of high ultraviolet-exposure activities (e.g., exposure to sunlight, tanning boxes, or other artificial light sources)
  • No history of keloid formation



  • 20 to 60

Performance status:

  • Not specified

Life expectancy:

  • Not specified


  • WBC ≥ 3,500/mm^3
  • Hemoglobin ≥ 12.0 g/dL
  • No bleeding disorder


  • Bilirubin ≤ 20% above upper limit of normal (ULN)
  • AST and ALT ≤ 20% above ULN
  • No chronic or acute hepatic disease


  • Creatinine ≤ 20% above ULN
  • No chronic or acute renal disease


  • No active gastrointestinal disease (e.g., inflammatory bowel disease)
  • No pancreatic disease
  • No esophageal, gastric, pyloric channel, or duodenal ulceration


  • No invasive cancer except nonmelanoma skin cancer cured by excision or stage I cervical cancer
  • No hypersensitivity or adverse reactions to NSAIDs, salicylates, cyclo-oxygenase-2 (COX-2) inhibitors, or sulfonamides
  • No condition that would preclude the use of NSAIDs
  • No clinically significant laboratory abnormalities
  • No medical or psychosocial condition that would preclude study participation
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile participants must use effective contraception


Biologic therapy:

  • No concurrent chemo-immunotherapy


  • See Biologic therapy
  • At least 1 year since prior chemotherapy, including topical fluorouracil

Endocrine therapy:

  • At least 2 weeks since prior topical glucocorticoids
  • At least 30 days since prior systemic corticosteroids
  • No concurrent systemic glucocorticoids (inhaled corticosteroids allowed)
  • No concurrent topical corticosteroids
  • No concurrent hormonal therapy
  • Hormone replacement (e.g., estrogen or thyroid replacement) allowed


  • No concurrent radiotherapy


  • Not specified


  • At least 14 days since prior aspirin (> 100 mg/day) or other non-steroidal anti-inflammatory drugs (NSAIDs) taken at least 3 times per week
  • At least 2 weeks since prior topical alpha hydroxy acids (e.g., glycolic acid or lactic acid)
  • At least 6 months since prior oral retinoids (3 months for topical retinoids to the face)
  • At least 30 days since prior treatment for esophageal, gastric, pyloric channel, or duodenal ulceration
  • At least 30 days since prior investigational medication
  • No other concurrent investigational medication
  • No concurrent topical vitamin A derivatives and/or alpha hydroxy acids
  • No concurrent immunosuppressive drugs
  • No concurrent topical medication to the skin, including prescription and over-the-counter preparations (moisturizers and emollients allowed)
  • No concurrent lithium, fluconazole, or warfarin
  • No concurrent chronic NSAIDs (> 3 times per week for > 2 consecutive weeks per year)
  • Concurrent cardioprotective doses of aspirin (≤ 100 mg/day) allowed
  • Concurrent acetaminophen allowed
  • No concurrent green tea consumption of > 2 cups per day
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00025051

United States, New York
Herbert Irving Comprehensive Cancer Center at Columbia University
New York, New York, United States, 10032
Sponsors and Collaborators
National Cancer Institute (NCI)
Study Chair: David R. Bickers, MD Herbert Irving Comprehensive Cancer Center
  More Information Identifier: NCT00025051     History of Changes
Other Study ID Numbers: CDR0000068840
Study First Received: October 11, 2001
Last Updated: March 21, 2013

Keywords provided by National Cancer Institute (NCI):
basal cell carcinoma of the skin
squamous cell carcinoma of the skin

Additional relevant MeSH terms:
Skin Neoplasms
Neoplasms by Site
Skin Diseases
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents processed this record on April 24, 2017